Breaking News Instant updates and real-time market news.

VBLT

VBL Therapeutics

04:55
10/06/17
10/06
04:55
10/06/17
04:55

VBL Therapeutics management to meet with Roth Capital

Meeting to be held in San Francisco on October 6 hosted by Roth Capital.

  • 06

    Oct

  • 10

    Oct

VBLT VBL Therapeutics

11/29/16
ROTH
11/29/16
NO CHANGE
ROTH
VBL Therapeutics mentioned positively at Roth Capital
11/29/16
ROTH
11/29/16
NO CHANGE
Target $17
ROTH
Buy
VBL Therapeutics thyroid study points in right direction, says Roth Capital
Roth Capital analyst Joseph Pantginis notes that VBL Therapeutics has announced positive follow-up overall survival data from the Phase 2 thyroid cancer study with VB-111. The analyst believes VB-111 represents a "strong potential option" for patients with recurrent glioblastoma and looks forward to clinical progress in the Phase 3 rGBM study. Pantginis projects upside from future clinical updates, expansion opportunities for new indications as well as partnership potential for VB-111. He reiterates a Buy rating and $17 price target on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.